FAAH Inhibitor

URB524 is an irreversible FAAH inhibitor of O-aryl amino acid esters. URB524 inhibits FAAH by aminoformylation of Ser241. URB524 exhibits analgesic, antidepressant, and anti anxiety activity.

FAAH inhibitor 1 (Standard) is the analytical standard of FAAH inhibitor 1 (HY-10862). This product is intended for research and analytical applications. FAAH inhibitor 1 (compound 3) is a selective reversible FAAH inhibitor. FAAH inhibitor 1 has no off-target activity with respect to other serine hydrolases. FAAH inhibitor 1 is exclusively specific against FAAH in rat brain with an IC₅₀ value of 18 nM and had no missing protein bands in all the other tissues. FAAH inhibitor 1 can be used for neurological disorders research.

OL-135 is a CNS penetrant, selective, and reversible of FAAH inhibitor. OL-135 exhibits analgesic activity.

FAAH-IN-8 (compound 11) is a competitive inhibitor of FAAH with an IC₅₀ value of 6.7 nM and a K_i value of 5 nM. FAAH-IN-8 has high blood-brain permeability and a significant antioxidant profile with no neurotoxicity.

FAAH inhibitor 2 (Compound 17b) is an irreversible fatty acid amide hydrolase (FAAH) inhibitor, with an IC₅₀ of 0.153 μM.

LY2183240 (Standard) is the analytical standard of LY2183240 (HY-10865). This product is intended for research and analytical applications. LY2183240 is a highly potent blocker of anandamide uptake (IC₅₀= 270 pM; K_i=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) with an IC₅₀ of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC₅₀s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and K_iAA1363, respectively .

JZL195 (Standard) is the analytical standard of JZL195. This product is intended for research and analytical applications. JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively.

JNJ-40413269 is an inhibitor for FAAH, that inhibits human FAAH and rats FAAH with IC₅₀ of 28 nM and 270 nM. JNJ-40413269 exhibits analgesic efficacy in rat spinal nerve ligation model and exhibits good pharmacokinetic characteristics in rats.

FAAH-IN-9 (compoud 59) is an irreversible oleoyl inhibitor of FAAH with Ki of 0.02 nM.

MK-3168 (12C) is a FAAH inhibitor with IC₅₀ values of 1.0, 5.5, 1.7 nM for human, rhesus, rat, respectively. MK-3168 shows good brain uptake and FAAH-specific signal. ¹¹C MK-3168 can be used as FAAH PET tracer.

CAY10435 is a β-ketooxazapyridine, selective FAAH inhibitor with antimicrobial activity. CAY10435 binds non-competitively to the FAAH of Dictyostelium discoideum with a Kd value of 0.57 nM.

JNJ-42165279 (dihydrochloride) is aFAAHinhibitor with IC₅₀ of 70 nM and 313 nM for hFAAH and rFAAH, respectively.

URB-597 (Standard) is the analytical standard of URB-597. This product is intended for research and analytical applications. URB-597 (KDS-4103) is an orally bioavailable and selective FAAH inhibitor. URB-597 inhibits FAAH activity with an IC50s of approximately 5 nM in rat brain membranes, 0.5 nM in intact rat neurons, 3 nM in human liver microsomes. Antidepressant-like effects. Analgesic activity.

AZ513 is a reversible FAAH inhibitor with an IC₅₀s of 551 nM and 27 nM for human FAAH and rat FAAH, respectively. AZ513 inhibits Anandamide (HY-10863) hydrolysis in human FAAH-transfected HEK293 cells (IC₅₀ of 360 nM).

FAAH-IN-1 (Standard) is the analytical standard of FAAH-IN-1 (HY-111389). This product is intended for research and analytical applications. FAAH-IN-1 is a fatty acid amide hydrolase (FAAH) inhibitor, with IC₅₀s of 145 nM and 650 nM for rat and human FAAH, respectively.

1-Monomyristin, extracted from Serenoa repens, inhibits the hydrolysis of 2-oleoylglycerol (IC50=32 μM) and fatty acid amide hydrolase (FAAH) activity (IC50=18 μM). 1-Monomyristin shows antibacterial activity against Staphylococcus aureus and Aggregatibacter actinomycetemcomitans and also antifungal activity against Candida albicans.

PHOP is a fatty acid amide hydrolase (FAAH) inhibitor used to assess inhibitory activity in a fluorometric assay. PHOP can determine FAAH activity by measuring the amount of 4-pyridin-1-ylbutyric acid released by the enzyme in rat brain microsomes. PHOP demonstrates potential as a FAAH inhibitor and can directly measure FAAH activity by reversed-phase HPLC and fluorescence detection, providing a basis for the development of new inhibitors.

Redafamdastat (Standard) is the analytical standard of Redafamdastat. This product is intended for research and analytical applications. Redafamdastat (PF-04457845) is a highly efficacious and selective FAAH inhibitor with IC50 values is 7.2±0.63 nM and 7.4±0.62 nM for hFAAH and rFAAH, respectively.

Carmofur (Standard) is the analytical standard of Carmofur. This product is intended for research and analytical applications. Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC₅₀ of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI).

FAAH-IN-2 (Standard) is the analytical standard of FAAH-IN-2. This product is intended for research and analytical applications. FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is an inhibitor of FAAH. FAAH-IN-2 is a metabolite of Gefitinib (HY-50895).